Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01644994
Other study ID # INFLuenCe - Meso
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date November 2012
Est. completion date August 2021

Study information

Verified date September 2021
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim is to introduce a new therapeutic method of intracavitary chemotherapy (cisplatin) combined with a fibrin carrier (Vivostat®) after pleurectomy/decortication or extrapleural pneumonectomy in a phase I and II study for Malignant Pleural Mesothelioma patients by evaluation of the safety in a dose-escalating model (phase I), and confirmation of safety and efficacy in phase II with the maximum tolerated dose in phase I.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date August 2021
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Patient is able to understand and willing to sign a written informed consent document. - Male or female, age >=18 years - ECOG performance status =<2 (ECOG = Eastern Cooperative Oncology Group) - Resectable MPM (Malignant Pleural Mesothelioma) histologically confirmed (phase I: stage cT1-cT4 cN0-cN3 cM0-cM1 / phase II: stage cT1-cT3 cN0-cN1 cM0) (TNM Tumor staging abbreviations: c = clinical; T = Tumor, N = lymph Nodes, M = Metastases; numbers = quantity) - Only Phase II: Mediastinal staging (cytological or histological) - Only Phase II: Induction chemotherapy (3 or more cycles cisplatin or carboplatin (also in combination with other therapeutic agents) - Patient qualifying for (extended) pleurectomy/decortication ((e)P/D) or extrapleural pneumonectomy (EPP) for resection of MPM, which has to be assessed during a multidisciplinary tumor board including a thoracic surgeon - Patient must have appropriate organ and bone marrow function as defined: hematologic function: hemoglobin =100 g/L, WBC (white blood cell count) =3.5 G/L, neutrophils =1.5 G/L, thrombocytes =100 G/L; liver function: total bilirubin and LDH (lactate dehydrogenase) =1.5 x ULN (upper limit of normal); AST (aspartate aminotransferase), ALT (alanine aminotransferase), GGT (gamma glutamyltransferase), and AP (alkaline phosphatase) =2.5 x ULN; renal function: creatinine =130 µmol/L or, if greater, creatinine clearance =60 ml/min/1.73m2. - Patient must have an appropriate blood coagulation for P/D or EPP (Quick-test > 50%, INR (international normalized ratio) <=1.2) - The patient agrees to use an efficient contraceptive treatment up to 3 months after cisplatin application if required (pre-menopausal women and men in a sexually mature age). - Heart and lung function allowing P/D under general anesthesia Exclusion criteria: - Known or suspected unwillingness of the patient to follow the rules of the protocol - Patient who has not recovered from side effects from prior chemotherapy or radiotherapy. - Any known hypersensitivity against cisplatin or other platinum containing substances or any other components used for the preparation of the drugs. - Patient must not receive any other investigational agents 4 weeks before treatment and until the end of the observation period (2 months after treatment). - Patient with prior ipsilateral pleurectomy - Only Phase II: Multimodality Prognostic Score (MMPS) > 2: 4 items with a maximum possible score of 4 if the patient presented all four conditions and 0 if none were present: Tumor volume before induction chemotherapy > 500 ml, non-epithelioid histotype in the diagnostic biopsy before induction chemotherapy, CRP (C reactive protein) value > 30 mg/l before induction chemotherapy, and progressive disease after induction chemotherapy according to RECIST criteria - Patient with uncontrolled intercurrent illnesses that would limit the operative procedure of P/D / EPP or compliance with study requirements - Tinnitus impairment of more than severity grade I (slight) evaluated by the tinnitus questionnaire MiniTF12_CH (Mini Tinnitus Fragebogen 12, CH = Confoederatio Helvetica (Swiss version)), and/or restricted power of hearing until 4 kHz (kilohertz) confirmed by audiometry, unless age-related presbyacusis in a normal range confirmed by an audiologist. - Known alcohol and/or drug abuse at the time of screening - Pregnant or lactating woman

Study Design


Intervention

Combination Product:
intracavitary cisplatin-fibrin
single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication

Locations

Country Name City State
Switzerland University Hospital Zurich, Division of Thoracic Surgery Zurich ZH

Sponsors (3)

Lead Sponsor Collaborator
University of Zurich Swiss Accident Insurance Fund SUVA, Swiss National Science Foundation

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other pharmacokinetics cisplatin concentration in pleural effusion cisplatin concentration in pleural effusion by inductively coupled plasma sector field mass spectrometric (ICP-MS) detection Pleural effusion collection: 0-48 h postoperative
Primary Incidence of Treatment-Emergent Adverse Events (Safety) (Serious) Adverse Events & safety blood parameters (hematology and clinical chemistry) during 6 weeks after surgery with local cisplatin-fibrin application
Primary Cisplatin concentration in the superficial chest wall tissue local cisplatin concentration in the superficial chest wall biopsy measured by inductively coupled plasma sector field mass spectrometric (ICP-MS) detection 90 min after application
Secondary overall survival time between date of treatment and time point of death or last follow-up, method of Kaplan and Meier up to 5 years (phase I), up to 2 years (phase II)
Secondary FFR (= Freedom From Recurrence) time to tumor progression by CT or PET-CT/MRI, method of Kaplan and Meier 4, 16 weeks, then every 4 months up to 5 (phase I) / 2 years (phase II)
Secondary in-treatment-field FFR (= Freedom From Recurrence) time to tumor progression by CT or PET-CT/MRI in the chest cavity where the investigational medicinal product was applied, method of Kaplan and Meier (PET-CT = positron emission computed tomography) up to 2 years (phase II)
Secondary Quality of Life SF-36 (= Short Form-36) change from baseline in SF-36 quality of life questionnaire phase I: 0, 4, 8, 16 weeks and every 4w up to 5y; phase II: 0, 6, 16w and every 4w up to 2y
Secondary Quality of Life EORTC QLQ-C15/LC13 (QLQ = Quality of Life Questionnaire, C = Cancer, LC = Lung Cancer) change from baseline in EORTC Lung Cancer Questionnaire QLQ-C15/LC13 phase I: 0, 4, 8, 16 weeks and every 4w up to 5y; phase II: 0, 6, 16w and every 4w up to 2y
Secondary pharmacokinetics cisplatin concentration in blood serum cisplatin concentration in blood serum by inductively coupled plasma sector field mass spectrometric (ICP-MS) detection baseline, and 0, 2, 6, 10, 24, 48, 120 h postoperative
Secondary pharmacokinetics cisplatin concentration in urine pharmacokinetics, cisplatin concentration in urine by inductively coupled plasma sector field mass spectrometric (ICP-MS) detection baseline, collection of first 48h, day 14 postoperative
Secondary TUNEL assay markers for apoptosis in superficial chest wall tissue before and 90 min after cisplatin-fibrin application
Secondary PAI-1 and p21 (PAI-1 = Plasminogen Activator Inhibitor Typ 1, p21 = CDK-Inhibitor 1 = Cyclin Dependent Kinase Inhibitor 1)) markers for senescence in superficial chest wall tissue before and 90 min after cisplatin-fibrin application
See also
  Status Clinical Trial Phase
Recruiting NCT06037941 - Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma N/A
Completed NCT01675765 - Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Phase 1
Withdrawn NCT04201145 - Pembrolizumab + Defactinib In Pleural Mesothelioma Phase 1
Completed NCT03048474 - Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma Phase 2
Completed NCT02369198 - MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC Phase 1
Terminated NCT01870609 - Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT00886028 - Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Phase 2
Completed NCT00272558 - Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT02436733 - Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM Phase 2
Completed NCT04843007 - Alvopem® (Pemetrexed) Safety Assessment
Completed NCT01721018 - Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Phase 1/Phase 2
Active, not recruiting NCT00797719 - Short Neoadjuvant Hemithoracic IMRT for MPM Phase 1/Phase 2
Completed NCT00386815 - Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Phase 2
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT04775446 - Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Completed NCT01865045 - Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Completed NCT00571298 - Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma Phase 1
Recruiting NCT01343264 - Trimodality Therapy for Malignant Pleural Mesothelioma N/A
Active, not recruiting NCT04162015 - A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Phase 1
Recruiting NCT04400539 - The IMmunotherapy Pleural 5-ALA PDT Phase 2